HGH vs tesamorelin: what the research says

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any peptide or hormone therapy.

A question that surfaces regularly in the r/peptides community runs something like this: six months of tesamorelin went well for body composition. Now there is access to actual somatropin (recombinant human growth hormone). And there is also an IVF cycle on the horizon. Which do you use, when, and does the IVF question change anything? The question is worth answering carefully, because HGH and tesamorelin work through different mechanisms, carry different regulatory footprints, and the IVF literature on growth hormone is far more limited than the marketing around it suggests.

HGH and tesamorelin: same axis, different entry points

Recombinant human growth hormone (rhGH, sold under brand names including Genotropin, Norditropin, and Humatrope) is an injectable copy of the full growth hormone protein. Inject it and GH appears directly in the bloodstream, bypassing the hypothalamic-pituitary axis entirely. The FDA labels for somatropin products are approved for specific medical conditions including adult-onset growth hormone deficiency, not for body composition in otherwise healthy adults^[1]. Because the pituitary detects the elevated circulating GH, it reduces its own pulsatile secretion. The result is that endogenous GH output can fall during periods of exogenous rhGH use.

Tesamorelin works upstream. It is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the 44-amino-acid signal the hypothalamus uses to prompt the pituitary to release GH. Rather than delivering GH directly, tesamorelin stimulates the pituitary to produce its own GH in roughly normal pulses. In the phase-3 randomised trials that led to FDA approval for HIV-associated lipodystrophy, mean IGF-1 rose by approximately 108 ng/mL from baseline over 26 weeks, versus no meaningful change on placebo (P less than 0.001)^[2]. The pituitary-upstream mechanism is why some clinicians describe tesamorelin as a more physiological approach: the pulsatile pattern is preserved.

The practical consequence when considering a transition: if you have used exogenous rhGH for a sustained period, your pituitary may have down-regulated its own GH secretion. Switching to tesamorelin at that point means relying on a pituitary that may be temporarily blunted. There is no published clinical data characterising this transition scenario, so any prediction about outcome would be speculation.

Body composition: what the trial record actually says

The body-composition case for tesamorelin rests on the HIV-associated lipodystrophy programme, a population with a specific and well-characterised visceral fat phenotype. The effect on visceral adipose tissue in that population was real and statistically significant. The effect on subcutaneous fat (the fat most people see in the mirror) was much smaller. Extrapolating from a specialised disease population to body-recomposition use in otherwise healthy adults is a leap the published literature does not support.

For rhGH, the off-label body-composition literature is larger but methodologically messy: small trials, variable doses, short durations, and selective reporting. The consistent finding across that literature is that rhGH reduces visceral fat and increases lean mass modestly in the short term, but fluid retention, carpal tunnel symptoms, insulin resistance, and joint pain are common adverse effects. The FDA-approved indications for somatropin products do not include body recomposition in healthy adults, and the label carries prominent warnings about diabetes risk and malignancy concerns in patients with pre-existing conditions.

Growth hormone and IVF: what the evidence shows

The use of growth hormone as an adjuvant in IVF cycles has been studied for over two decades, primarily in women classified as poor ovarian responders. A 2021 Cochrane systematic review of 16 randomised controlled trials (1,352 women) found that GH adjuvant therapy in poor responders was associated with a modest improvement in clinical pregnancy rates (from a baseline of roughly 15 percent to an estimated range of 19 to 31 percent), but rated the evidence as very low certainty due to small trial sizes, high risk of bias, and inconsistent GH dosing across studies^[3]. For the general IVF population without defined poor response, the same review found no clear benefit.

Several points follow from this. First, the IVF-relevant GH literature uses recombinant somatropin, not tesamorelin. There are no IVF trials with tesamorelin. A GHRH analogue used in the IVF context is an unstudied extrapolation. Second, even for somatropin, the evidence base is weak enough that major reproductive medicine bodies have not endorsed routine GH adjuvant use outside poor-responder populations. Third, the timing of the IVF cycle matters: GH is typically administered during the stimulation phase under a specific protocol managed by a reproductive endocrinologist. It is not something that carries over from a separate body-composition cycle.

If you and your partner are planning an IVF cycle and considering GH adjuvant therapy, the decision belongs with your reproductive endocrinologist, who will know your response profile from prior cycles and whether you meet the criteria for poor responder classification. Bringing your tesamorelin or rhGH history to that consultation is the right move.

Stacking with tirzepatide: an open question

Some members of the community run tirzepatide alongside GH-axis peptides. There is no published human trial examining the interaction between tirzepatide (a dual GIP and GLP-1 receptor agonist) and any somatropin product or GHRH analogue. Preclinical and mechanistic reasoning can be applied, but it is not a substitute for clinical data. Tirzepatide already produces meaningful changes in body composition through independent mechanisms, and layering GH-axis agents on top creates a pharmacological picture that no published study has characterised for safety or additive benefit.

A clinician who knows your labs, your history with each compound, and the IVF timeline is the right person to hold this conversation with. The combination of active body-composition work, a fertility cycle, and multiple peptides or hormones simultaneously is not a scenario that has been studied, and the stakes in the fertility context are high.

What to ask your clinician

If you are in this situation or something like it, the questions worth raising are: What is my current IGF-1 and baseline GH status after six months of tesamorelin? Has my pituitary output recovered if I have been on tesamorelin daily? What is my reproductive endocrinologist's view on GH adjuvant use given my specific response profile? If the IVF cycle is active or imminent, should I pause any GH-axis agent until the cycle is complete? What are the informed-consent boundaries of running tirzepatide alongside a fertility cycle?

For the regulatory picture on tesamorelin by country (it is FDA-approved in the US for a specific indication and has no EU or UK marketing authorisation), see the tesamorelin page on this site. The regulatory status of somatropin products varies by country and by indication.